Drugs Xagena
Access to Trasylol ( Aprotinin ) is limited to investigational use of the drug according to the procedures described in a special treatment protocol. The protocol allows treatment for certain patients who are at increased risk of blood loss and transfusions during coronary artery bypass graft surgery and who have no acceptable alternative therapy. Physicians using Trasylol in this situation must also verify that the benefits of the drug clearly outweigh the risks for their patients.
FDA ( Food and Drug Administration ) limits access to certain drugs to patients with serious or immediately life-threatening disease or conditions who lack other therapeutic options and may benefit from such therapies. This type of access requires the submission of a protocol, which is reviewed and approved by the agency.
Bayer has agreed to provide Trasylol through this mechanism for the limited use described above.
Trasylol is an antifibrinolytic drug approved to reduce blood loss during surgery and the need for blood transfusion in certain patient undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery. Antifibrinolyitic drugs help slow the breakdown of blood clots and subsequent excessive bleeding.
Results from a randomized Canadian study that prompted last Novembers marketing suspension of Trasylol are published in the New England Journal of Medicine. The data contained in this article suggest that Trasylol appears to increase the risk for death compared to two other antifibrinolytic drugs used in the study.
The findings from this randomized study are similar to those from an observational study that was discussed at a September 2007 FDA Advisory Committee meeting. Based upon the data available at the time, the Advisory Committee recommended continued marketing of Trasylol. However, FDA requested the marketing suspension in the interest of patient safety based on the serious nature of the outcomes suggested in the preliminary data. The Committee also advised that a large, randomized clinical study was needed to further assess Trasylols safety compared to other drugs.
The FDA has not yet received full study data from the studys researchers at the Ottawa Health Research Institute but supports Bayers decision to completely remove Trasylol from regular use in the U.S. market. FDA is also reviewing the available Canadian study data to reassess the currently active special treatment protocol that provides access to Trasylol.
Source: FDA, 2008
XagenaMedicine_2008
